The findings of our study propose that PIK3CA mutation could be a predictive marker for the response to abemaciclib and BYL719 combination therapy in colorectal cancer treatment, and it should be validated in further preclinical and clinical trials. Here, PIK3CA is linked to colorectal cancer.